Keywords: Biogen Idec, Abbott Labs, Daclizumab, Ph IIb, Multiple sclerosis, MS

Biogen Idec and Abbott MS drug candidate daclizumab positive in Ph IIb

Article | 10 August 2011

Print This

US biotech Biogen Idec (Nasdaq: BIIB) and health care giant Abbott Laboratories (NYSE: ABT ) have announced positive top-line results from ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in